6 results
10-K
2021 FY
THRX
Theseus Pharmaceuticals Inc
10 Mar 22
Annual report
7:23am
and technologies. We also rely on trade secrets, know-how and continuing technological innovation to develop and maintain our proprietary and intellectual … therapeutic, scientific or technical innovation or which are in the interest of public health in the EU.
National MAs, which are issued by the competent
424B4
THRX
Theseus Pharmaceuticals Inc
7 Oct 21
Prospectus supplement with pricing info
5:03pm
and technologies. We also rely on trade secrets, know-how and continuing technological innovation to develop and maintain our proprietary and intellectual … not authorized in the EEA prior to May 20, 2004, is a significant therapeutic, scientific or technical innovation, or if its authorization would
S-1/A
THRX
Theseus Pharmaceuticals Inc
30 Sep 21
IPO registration (amended)
6:33am
and technologies. We also rely on trade secrets, know-how and continuing technological innovation to develop and maintain our proprietary … substance not authorized in the EEA prior to May 20, 2004, is a significant therapeutic, scientific or technical innovation, or if its authorization
S-1
THRX
Theseus Pharmaceuticals Inc
15 Sep 21
IPO registration
4:04pm
development processes and technologies. We also rely on trade secrets, know-how and continuing technological innovation to develop and maintain our … , scientific or technical innovation, or if its authorization would be in the interest of public health in the EEA. If pursuing marketing authorization
DRS/A
THRX
Theseus Pharmaceuticals Inc
23 Aug 21
Draft registration statement (amended)
12:00am
technological innovation to develop and maintain our proprietary and intellectual property position. We also plan to rely on data exclusivity, market … in the EEA prior to May 20, 2004, is a significant therapeutic, scientific or technical innovation, or if its authorization would be in the interest
DRS
8b0i14a
20 Jul 21
Draft registration statement
12:00am
- Prev
- 1
- Next